BiotechTube
STORM Therapeutics

STORM Therapeutics

Cambridge, United Kingdom· Est.
stormtherapeutics.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $50M

Overview

STORM Therapeutics is a private, clinical-stage biotech founded in 2015, operating at the forefront of the emerging RNA epigenetics space. Its core strategy is to drug RNA modifying enzymes (RMEs), a vast and largely untapped class of targets, to develop novel oncology therapeutics. The company has advanced programs into the clinic and is actively forming strategic partnerships to accelerate development. STORM represents a high-risk, high-reward venture targeting a novel mechanism with significant potential in oncology and beyond.

Oncology

Technology Platform

Proprietary platform for discovering and developing small molecule inhibitors targeting RNA modifying enzymes (RMEs), integrating target biology, structural biology, and medicinal chemistry.

Funding History

3
Total raised:$50M
Series B$30M
Series A$16M
Seed$4M

Opportunities

RNA epigenetics is a vast, novel target space with over 300 enzymes, offering first-mover advantage in developing a new class of oncology drugs.
The platform has potential applications beyond cancer in virology, neurology, and metabolic diseases, creating significant long-term optionality.
Strategic partnerships, like the one with AlidaBio, can accelerate development, validate the approach, and provide non-dilutive funding.

Risk Factors

The core risk is the novel and unproven biology; inhibiting RNA modifying enzymes may lead to unexpected toxicity or lack of efficacy in humans.
As a pre-revenue private company, it faces significant financing and execution risk in costly clinical development.
The competitive landscape is intensifying as larger pharmaceutical companies and other biotefts begin exploring the epitranscriptomic space.

Competitive Landscape

STORM is an early leader but not alone in the epitranscriptomics field. Competitors include other biotechs like Accent Therapeutics (US) and Gotham Therapeutics (US), as well as research initiatives within large pharma (e.g., AstraZeneca, Pfizer). Competition is for target validation, intellectual property, and clinical proof-of-concept. The landscape is currently fragmented but poised for consolidation as the field matures.

More companies in Small Molecule Drugs →More companies in United Kingdom →